Waite A, Balkman C, Bailey D, Kiselow M, Flory A, Beaulieu B B, Lewis L D, McEntee M
Cornell University Hospital for Animals, College of Veterinary Medicine, Ithaca, NY, USA.
Vet Comp Oncol. 2014 Jun;12(2):160-8. doi: 10.1111/j.1476-5829.2012.00350.x. Epub 2012 Aug 21.
The goal of the current study was to determine the efficacy of oral docetaxel in combination with cyclosporine in the treatment of canine epithelial cancer. Requirements for eligibility were histological confirmation of epithelial neoplasia, measurable disease, no chemotherapy treatment within 2 weeks, and a life expectancy of ≥ 3 months. Fifty-one dogs were enrolled. All dogs received 1.625 mg kg(-1) of docetaxel with 5 mg kg(-1) of cyclosporine (DT/CSA) by gavage. Ten dogs had progressive disease at 2 weeks, one dog died, and one dog was withdrawn from the study. Thirty-nine dogs were given a second dose of DT/CSA, three each receiving a third or fourth dose. Eight dogs had a dose reduction (1.5 mg kg(-1)) and six dogs had treatment delays primarily for gastrointestinal toxicity. The overall response rate was 16.7% (8/48 had a partial response there were no complete responses). The highest response rate was seen in dogs with oral squamous cell carcinoma (50%; 6/12).
本研究的目的是确定口服多西他赛联合环孢素治疗犬上皮癌的疗效。入选标准为上皮肿瘤的组织学确诊、可测量的疾病、2周内未接受化疗治疗以及预期寿命≥3个月。51只犬被纳入研究。所有犬均通过灌胃给予1.625 mg kg(-1)的多西他赛和5 mg kg(-1)的环孢素（DT/CSA）。10只犬在2周时病情进展，1只犬死亡，1只犬退出研究。39只犬接受了第二剂DT/CSA，3只犬分别接受了第三或第四剂。8只犬剂量减少（1.5 mg kg(-1)），6只犬主要因胃肠道毒性而延迟治疗。总缓解率为16.7%（48只中有8只部分缓解，无完全缓解）。口腔鳞状细胞癌犬的缓解率最高（50%；12只中有6只）。
